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ABSTRACT 
Epstein-Barr virus (EBV) infects majority of the human population and 
maintains sub-clinical infection. However, under certain conditions it is associated with several 
B-cell malignancies, such as Burkitt lymphoma, Hodgkin’s lymphoma etc. Moreover, EBV 
also plays a causative role in acquired immunodeficiency syndrome (AIDS) associated 
lymphomas and post-transplant lymphoproliferative disease (PTLD). EBV maintains latent 
infection and expresses a particular set of proteins that are necessary for host cell proliferation. 
Studying function of EBV latent proteins could help us to understand the mechanisms 
underlying EBV induced B-cell transformation. 
EBV transformed B cells, i.e. lymphoblastoid cell lines (LCLs) is a well-
established in vitro model system to study the molecular mechanisms of B-cell transformation. 
In the present work, we have identified vitamin D receptor (VDR) as a binding partner of 
EBNA3. We showed that EBNA3 can block the VDR mediated gene transactivation and 
protects B-cells from vitamin D3 induced growth arrest/ apoptosis. We have observed that 
hypoxia inducible factor 1 alpha (HIF1) is stabilized in LCLs at normoxic conditions. 
HIF1is not hydroxylated and therefore it is not degraded in LCLs. We have shown that 
prolylhydroxylases 1 and 2 (PHD1 and 2) that are responsible for hydroxylation of 
HIF1form complexes with andrespectivelyDue to this binding catalytic 
activity of PHDs is blocked, resulting in inhibition of HIF1hydroxylation and subsequent 
degradation. Stabilized HIF1is transcriptionally active and induces genes that are involved in 
glycolysis. Moreover, LCLs have high levels of pyruvate and lactate in contrast to mitogen 
activated B cells, indicating induction of aerobic glycolysis or Warburg effect. 
We have shown that mitochondrial ribosomal protein MRPS18-2 (S18-2), an 
EBNA6 binding protein, can immortalize rat embryonic fibroblasts (REFs). These 
immortalized cells express stem cell markers like SSEA1, Sox2, Oct3/4 and have the 
characteristics of embryonic stem cells. S18-2 also immortalized the adult rat skin fibroblasts 
(RSFs). Moreover, single clones from immortalized REFs and RSFs resulted in tumors in 
SCID mice.       
 This thesis work reveals three different aspects of EBV induced B-cell 
transformation, i.e. protection from vitamin D3 induced apoptosis, metabolic adaptation 
required for proliferation and hijacking functions of novel protein MRPS18-2 for 
immortalization. 
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1 BACKGROUND 
Cancer is a major public health concern and the second leading cause of 
death resulting in 7.6 million deaths every year worldwide [1]. Disease of cancer was 
recognized for thousands of years and some of the earliest evidence of human bone 
cancer was found in 4 million–year-old fossilized hominid remains; nasopharyngeal 
carcinomas and osteogenic sarcomas were seen in ancient Egyptian mummies. The 
written records for the human cancer are found in Babylonian Code of Hammurabi 
(1750 BCE), ancient Egyptian papyri (1600 BCE), the Chinese Rites of the Zhou 
Dynasty (1100–400 BCE), and the ancient Indian Ramayana manuscript (500 BCE)[2]. 
Hippocrates is credited for the origin of word cancer. He used the terms carcinos and 
carcinoma, which means crab in Greek, to describe appearance of tumors. These Greek 
terms were then translated to Latin cancer by Roman physician Celsus.   
Scientific oncology advanced in the 19th century and with the 
development of microscopy, cancer could be studied at microscopic level. Cellular 
theory of cancer was established and in the same century infection was considered as an 
etiology for the cancer. Vilhelm Ellermann and Olaf Bang, two Danish scientists 
reported in 1908, that cell free filtrate of chicken leukemia passed on the disease in 
other chickens [3]. However, leukemia was not considered as cancerous at that time 
and so causative virus was not considered to be a tumor virus. Three years later, in 
1911, Payton Rouse at the Rockefeller Institute reported another avian malignancy- a 
sarcoma developing in Plymouth Rock fowls could be transmittable to healthy chickens 
by cell free filtrates from tumor cells. Unlike leukemia, the avian sarcoma was shown 
to be genuine cancer by Rouse [4]. Thus Rouse sarcoma virus (RSV), as it is called 
now, became the first known tumor virus. In 1964, Epstein-Barr virus (EBV) was 
discovered in malignant cells of Burkitt lymphoma and is considered to be the first 
known human tumor viruses amongst many linked afterwards. 
Today we know that viruses are etiological agents of about 15 to 20 % of 
all cancers worldwide. Apart from pathogenesis of cancer, they have also served as an 
important discovery tools in tumor biology and have led to identification of many genes 
and cellular pathways involved in carcinogenesis. Both RNA (RSV, hepatitis C virus 
(HCV) etc) and DNA tumor viruses (EBV, human papilloma virus (HPV) etc) have 
been instrumental in development of current concept of tumor biology as well as 
identification of normal cellular growth pathways. They encode relatively fewer genes, 
induce tumors in animals and transform cells in culture and hence, are simple model 
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system to study [5]. Studying the first tumor virus has led to the development of the 
concept of oncogene and also discovery of the first oncogene, v-src [6]. On the other 
hand, DNA tumor viruses, like Epstein-Barr virus or human papilloma virus, have their 
own oncogenes of viral origin. p53 tumor suppressor protein was discovered with the 
help of DNA tumor virus SV40 (Simian virus 40) large T oncoprotein [7]. Often viral 
oncoproteins, like large T antigen of SV40, E6 and E7 of HPV, by physical interaction 
with cellular proteins block their function or perturb cellular pathways, leading to cell 
survival and that may result in oncogenic transformation of the host cell. Study of such 
viral oncoproteins and their interacting cellular proteins have immensely contributed 
and will continue to add in understanding of molecular mechanisms behind cellular 
transformation.   
In this doctoral thesis, we aimed to elucidate Epstein-Barr virus (EBV) 
strategies to induce cell transformation using EBV immortalized B-cell line, 
lymphoblastoid cell line (LCLs). We have shown that one of the viral proteins, 
EBNA3, via its binding with vitamin D receptor (VDR), blocks the activation of VDR-
responsive genes and protects LCLs against vitamin-D3-induced growth arrest and/or 
apoptosis [8]. We have observed that in LCLs, HIF1protein, which generally is 
degraded at the normal conditions, is stabilized and transcriptionally active. This 
finding has implication in metabolism in LCLs as HIF1 induces aerobic glycolysis, 
i.e. Warburg effect [9]. Overexpression of MRPS18-2 protein, that binds to Epstein-
Barr virus nuclear antigen 6 (EBNA6), can immortalize the primary rat embryonic 
fibroblasts and these cells show stem cells like characteristics [10, 11]. 
 
Figure 1: EBNA binding cellular proteins studied in this doctoral work and their functions. VDR- 
vitamin D receptor; PHDs- Prolyl hydroxylases. 
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1.1 EPSTEIN-BARR VIRUS BIOLOGY   
In 1958, British surgeon Denis Burkitt described a tumor common in sub-
saharan Africa which was later termed as Burkitt lymphoma (BL) [12]. It was initially 
linked to arthropod borne infectious agent, but in 1964, Epstein and co-workers 
identified herpes virus like particle with the help of electron microscope in a cell line 
established from BL biopsy. This virus was named as Epstein-Bar virus or human 
herpes virus 4 [13].  EBV is the first discovered human tumor virus and is linked to 
many lymphoid malignancies, such as Burkitt lymphoma, Hodgkins lymphoma, T-cell 
lymphomas, post-transplant lymphoproliferative disease (PTLD) and also some 
epithelial malignancies such as nasopharyngeal carcinoma (NPC) and gastric 
carcinoma [14].  
Epstein-Barr virus is a sole member of human lymphocryptovirus or 
gamma 1 herpes virus subfamily. EBV genome is composed of linear double stranded 
DNA of 184 kilo base pairs flanked with terminal repeats (TR) on both sides.  It 
encodes about 84 genes although EBV shows restricted gene expression pattern during 
latent infection in EBV associated malignancies [14]. Virus has co-evolved with the 
primate host for millions of years and it is a very efficient virus infecting over 90% of 
world’s adult human population.  
 
1.1.1 EBV latency programs  
EBV maintains latent infection in humans and shows different latency 
programs, which varies from full growth proliferative type III to the more restricted 
type II, type I or type 0. The type III latency program comprises six nuclear antigens 
EBNA 1-6, three latent membrane proteins LMP1, LMP2A and LMP2B plus two types 
of non-coding viral RNAs, EBERs (EBV-encoded non coding, non polyadenylated 
RNAs) and BARTs (BamH1-A rightward transcripts). This program is expressed by in 
vitro EBV infected B-cell lines, in vivo upon EBV infection of naive tonsillar B-cells 
[15], in posttransplant lymphoproliferative disease and in primary central nervous 
system lymphoma which arises in AIDS patients [16, 17].  In type II latency only 
EBNA1 and three latent membrane proteins are expressed and it is seen in vitro in EBV 
infected epithelial cells and in vivo in nasopharyngeal carcinoma and B-cell Hodgkin 
lymphoma. While in type I latency, just EBNA1 is expressed and is found in Burkitt 
lymphoma and in cell lines derived from Burkitt lymphoma. Type 0 may exists in EBV 
genome carrying circulating memory B-cells where lack of gene expression allows 
escape from T cell surveillance [18].    
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Table 1: Expression of latent proteins by EBV in different conditions. 
Latency type Latent genes and 
transcripts expressed 
Disease / condition 
0 No latent protein expressed Memory B-cells 
I EBNA1,EBERs, BARTs Burkitt lymphoma 
II EBNA1, LAMP1, LMP2A, 
LMP2B, EBERs and BARTs 
Nasopharyngeal carcinoma; 
Hodgkin’s disease, Gastric carcinoma 
III EBNA1-6, LMP1, LMP2A, 
LMP2B, EBERs and BARTs 
Infectious mononucleosis; 
Posttransplant lymphomas, AIDS-related 
lymphomas, Lymphoblastoid cell lines 
 
1.1.2 Function of the latent proteins 
1.1.2.1 EBNA1 
EBNA1 is the only EBV latent protein consistently expressed in all 
virally associated tumors. It is DNA binding nuclear phosphoprotein which recognizes 
plasmid replication origin, oriP which is necessary for replication and maintenance of 
episomal EBV genome [19, 20]. EBNA1 can also bind to viral promoters and 
negatively regulate its own expression [21]. EBNA1 plays a critical role in survival of 
Burkitt lymphoma cells by inhibiting apoptosis [22].   
 
1.1.2.2 EBNA2 
EBNA2 is one of the first viral protein expressed in EBV infected B-cells 
and is essential for B-cell transformation [23]. EBV strain P3HR-1, with deletion of 
EBNA2 gene is unable to transform B-cells in vitro. Restoration of EBNA2 in this 
strain transforms B-cells, this indicates the important role of EBNA2 in cell 
transformation [24, 25]. EBNA2 activates transcription of cellular genes like CD21, 
CD23 and viral genes such as LMP1, LMP2, EBNA3 family proteins, EBNA1, 2 and 5 
[26]. It does not bind directly to the DNA but form complex with ubiquitous DNA-
binding protein, RBP-Jk [27, 28]. EBNA2 can replace the intracellular part of Notch 
receptor and functionally mimic activated Notch [29]. In co-operation with EBNA5, 
EBNA2 induces progression of B-cells from G0 to G1 [23]. 
 
1.1.2.3 EBNA3 family 
EBNA3, 4 and 6 (also known as EBNA3A, 3B, and 3C) are the family of 
nuclear proteins tandemly arranged at the middle of the nuclear genome. They have 
slight similarity in amino acid sequence, similar gene structure and are transcribed from 
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the common promoter [30]. EBNA3 and 6 are essential for the B-cell transformation 
while EBNA4 is dispensable [31]. This family of proteins have been shown to inhibit 
the transactivation activity of the EBNA2 protein by competitively binding with RBP-
Jk and disrupting its binding with cognate Jk sequence and EBNA2 [27, 32-34]. 
EBNA6 has been shown to co-operate with (Ha-) ras in co-transfection assays to 
immortalize rat embryo fibroblasts (REFs) [35]. This family of proteins has been 
shown to disrupt the G2/M cell cycle checkpoint [36]. 
 
1.1.2.4 EBNA5  
EBNA5, also known as EBNALP, is one of the first viral gene expressed 
after B-cell infection along with EBNA2 [37]. It encodes a protein of variable size 
depending upon the number of BamHI repeats contained by a particular EBV isolate 
[38-40]. It is necessary for efficient transformation and clonal outgrowth of B-cell in 
vitro. EBNA5 stabilizes the level of p53 tumor suppressor by binding to protein MDM2 
and forming tri-molecular complex EBNA5-MDM2-p53 which could result into 
inhibition of transacriptional activity of p53 [41]. 
 
1.1.2.5 LMP1  
LMP1 is the major oncoprotein of EBV proven by its ability to transform 
rodent fibroblasts, being necessary for the B-cell transformation in vitro and 
tumorigenic ability in nude mice [26, 42, 43]. It has pleotropic effect on cells upon 
EBV infection resulting in increased homotypic adhesion, upregulation of B-cell 
activation markers [44], upregulation of anti-apoptotic proteins [45, 46], and stimulates 
the secretion of cytokines like IL-6, IL-8 [47]. LMP1 functions as constitutively 
activated receptor of tumor necrosis factor receptor (TNFR) superfamily, thus inducing 
downstream signaling cascade in ligand independent manner [48]. In vivo LMP1 can 
partially mimic functional properties of CD40, resulting in growth and differentiation 
responses in B-cells [49]. 
 
1.1.2.6 LMP2  
LMP2A and LMP2B are encoded by LMP2 gene which is formed by 
joining of the terminal repeats in circularized EBV episome as found in latently 
infected cells. Both the genes are not essential for the immortalization of B-cell in vitro 
[50] but it has been suggested that they play a role in viral persistence [18].  It has been 
shown in in vivo study that LMP2A can provide survival signals to B-cells in absence 
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of B-cell receptor (BCR), which otherwise would result in cell death [51]. This finding 
has been significant in the context of Hodgkins lymphoma which lacks functional B-
cell receptor and expresses LMP2A constitutively [52]. 
  
     
    Figure 2: Epstein-Barr virus modulation of cellular proteins. (Adapted from [53]). Scheme shows 
studies of viral latent proteins and cellular pathways modified by them. 
                                    
1.1.3 EBV infection in vivo 
Although EBV has been detected in tumors of B, T and epithelial cells, in 
healthy individuals it is mainly restricted to B-cell compartment. In healthy carriers 1-
50 per million B-cells are infected with EBV [54].  In vivo EBV follows the natural B-
cell biology to establish and maintain lifelong persistence in B-cell population. Most 
primary EBV infections occur in early childhood and they are usually asymptomatic. 
After primary infection EBV persists in the infected host who becomes a lifelong 
asymptomatic carrier. If the primary infection is delayed to adolescence EBV causes 
debilitating self-limiting syndrome known as infectious mononucleosis (IM). In 
infected person EBV is constantly or intermittently shed into the saliva and 
transmission occurs by close oral contact with the uninfected individuals [55], hence 
IM also called as kissing disease. Virus replicates in the epithelium of oropharynx and 
EBV infection of the B lymphocyte is believed to occur in the oropharyngeal lymphoid 
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organs. EBV interacts with CD21 receptor via its glycoprotein gp350. This follows 
with rapid proliferation and expansion of EBV positive B-cells which is brought under 
control by cytotoxic T cells (CTLs).  Naïve tonsillar B-cells are the population believed 
to express type III growth proliferative genes upon EBV infection. These EBV infected 
cells express CD80, a marker of activated proliferative lymphoblast [15]. These 
infected B-cells follow the natural B-cell activation biology similar to the activation of 
B-cells by an antigen. Activated B-cells expand into germinal centers and expression of 
LMP1 and LMP2A viral proteins which mimic the CD40 and BCR signaling 
respectively, provide the B-cell survival signals (otherwise result into apoptosis) in 
germinal centers [56]. B-cells then exit germinal centers as memory B-cells and these 
EBV infected cells transiently express EBNA1 but otherwise do not express any viral 
proteins and escape immune surveillance [18]. According to Thorley-Lawson model, 
germinal center B-cells can also exit and differentiate into plasma cells and these cells 
are the site of viral lytic reactivation [57]. Primary EBV infection induces both humoral 
and cellular immune response and antibodies are also produced against lytic as well as 
latent antigens. Despite immune mechanism, EBV persist latently in peripheral 
memory B-cell compartment and there is low level production of infectious virus in to 
saliva [55].  
 
1.1.4 EBV infection in vitro 
Henle and co-workers in 1967 found that virus can infect and immortalize 
B-cells in vitro transforming them in to lymphoblastoid cell line (LCL) [58, 59]. LCLs 
can also be generated by culturing peripheral blood lymphocytes from chronic virus 
carriers, provided the depletion of T cells with cyclosporine A [60]. This is associated 
with dramatic change in phenotype and behavior of cells in culture. The cell changes its 
morphology from the round small size to large irregular, develop villipodia and grow in 
tight clumps. These phenotypic changes are associated with entry into cell cycle and 
continuous proliferation. LCLs express type III latency genes that is sufficient to drive 
the cell proliferation and maintenance of the EBV genome. For initiation of 
immortalization, expression of only EBNA1, 2, 3, 5, 6 and LMP1 are required [24, 31, 
61, 62], and EBNA2 and LMP1 are also required for the maintenance of this state [63, 
64]. LCLs also show expression of B-cell activation markers CD23, CD30, CD39 and 
CD70 which are absent or expressed at very low levels on resting B-cells [65]. After 
the discovery that LCLs can be obtained by the EBV infection of B cells in vitro, this 
system became a model for B-cell transformation and it is believed that study on it can 
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explain EBV associated oncogenicity. EBV encoded latent nuclear antigens interact 
with the host cellular proteins and hijack their normal functions to promote the cell 
growth. Studying these protein-protein interactions has been instrumental in our 
understanding of various mechanisms behind the B-cell transformation by EBV. 
 
Figure 3: EBV life cycle, latency types and associated lymphoma. BL- Burkitt lymphoma; HL-
Hodgkin’s lymphoma; NPC-  nasopharyngeal carcinoma. (adapted from [66]) 
 
1.1.5 EBV and cancer 
EBV prevalence is much higher compared to associated tumors. Many of 
the EBV associated malignancies are geographically restricted, some occur in 
immunodefficient people while some requires other genetic alterations. However, many 
evidences support that EBV plays central role in associated malignancies. First its 
strong association with variety of malignancies and causal role in PTLD and AIDS 
associated lymphoma, second its ability to induce B-cell lymphoma in non-human 
primates, third to transform primary human B-cells in culture and finally because of its 
causal role in infectious mononucleosis which could lead to Hodgkin’s lymphoma [67]. 
Here we go through some of the EBV associated malignancies and pathogenic role of 
EBV in each one. 
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1.1.6 EBV associated lymphomas  
1.1.6.1 Burkitt lymphoma 
Burkitt lymphoma (BL) is common childhood tumor in equatorial Africa, 
also called as endemic form. Incidence elsewhere in the world is called sporadic from. 
There are geographical and ethnic variations as well as genetic factors associated with 
BL. EBV association is strongest in endemic BL (96% of cases) which shares 
epidemiological characteristics with the holoendemic malarial infection, which 
generally believed to explain geographical difference in the EBV association. Incidence 
of EBV associated BLs are rare (15%) in North America and Western Europe even in 
African population. While with intermediate incidence of around 50-70% of EBV 
associated BLs are found in North Africa and South America and Russia (discussed in 
[68]). BL also occurs in about 30-40% of HIV positive people [14] in the early stages 
of disease where immunosuppression is minimal [69]. Irrespective of the form and 
EBV association, all BL cells show one of the three chromosomal translocation (8:14, 
8:2 or 8:22) that places c-Myc regulation under the control of the immunoglobulin 
locus resulting in constitutive activation of the c-Myc oncogene [70]. Every third case 
of BL shows p53 mutation in small stretch of 33 amino acids (codons 213 to 248) [71, 
72] and there are genetic alterations in tumor suppressor retinoblastoma-like 2 (RB2) in 
most of endemic cases and some sporadic cases [73]. BL cells shows latency I viral 
gene expression program with only EBNA1 protein expressed along with EBERs and 
BamH1A transcripts [30].   
Since only EBNA1 nuclear protein is expressed in BL cells, the role of 
virus in pathogenesis of BL has been debated.  EBERs have been shown to induce 
expression of anti-apoptotic gene bcl-2 [74], induce interleukin 10 and facilitate 
resistance to interferon- BL cells phenotype matches with the centroblast, 
the antigen activated cells in lymphnodes which form germinal centers. These 
proliferating centroblasts undergo hypermutations and the recombinase genes RAG1 
and RAG2 play important role in this process. EBNA1 has been shown to upregulate 
these genes which might subsequently lead to genetic mutations and c-Myc 
translocation [77]. EBER expression is positively regulated by MYC. Thus expression 
of EBERs by centroblasts (which have acquired a c-Myc translocation and its 
constitutive activity) counteract pro-apoptotic effect of c-Myc [78]. Loss of EBV in 
Akata BL cells is associated with loss of tumorigenicity and re-establishment of type I 
latency can regain tumorigenicity in these cells [79].   
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1.1.6.2 Hodgkin’s lymphoma 
Hodgkin’s lymphoma (HL) comprises about 20% of all lymphomas in 
western world and it involves children in developing world and young adults in 
westernized society. HL is characterized by the disruption of normal lymph node 
architecture and the presence of 1-2% of malignant Hodgkin-Reed Sternberg (HRS) 
cells. Based on histology and immunophenotype of HRS cells, classical form of 
Hodgkin lymphoma is distinguished from a lymphocyte predominant form [80]. 
Lymphocyte predominant form is always EBV negative, while approximately 40% 
cases of classical HL are EBV positive. Association is higher in Latin America where 
nearly in all cases EBV is detected [81]. EBV is linked with HL because there is 
threefold increased risk of HL with history of IM [82] and HRS cells are also found in 
some cases of IM [83]. There is an altered pattern of serum antibodies to EBV before 
tumor development [84] and clonal EBV DNA was detected in HRS cells in 40% of 
HL [85]. EBV positive HL express restricted form of latency, with EBNA1, LMP1 and 
LMP2A protein expression, along with EBER and BamH1A transcripts [86]. 
 
1.1.6.3 Lymphoma in immunosuppressed patients 
T- cell immunocompromised individuals are at high risk of developing post-
transplant lymphoproliferative disease (PTLD) and it occur in 10 % of transplant 
patients and rarely in other immune-compromised patients [87]. High dose 
immunosuppressive therapies along with the primary EBV infection are the 
predisposing factors for PTLD. Suppression of T-cells allows uncontrolled proliferation 
of EBV transformed B-cells. Recipients who are EBV negative prior to transplant and 
undergo infection while immunosuppressed are at higher risk of developing disease. In 
such cases PTLD develop early after transplantation [88] and these tumors are 
polyclonal or oligoclonal. Almost all of the early developing tumors are EBV positive 
and express latency III viral expression program [89].  Post-transplant lymphoma can 
also develop many years after transplantation. EBV association in late onset PTLDs can 
fall below 50% and these tumors are monoclonal. Some of them express latency III 
gene expression program while others are EBNA2 and LMP1 negative or EBNA2 
negative but LMP1 positive for a proportion of cells [90, 91]. Lymphomas are also very 
common in AIDS patients particularly at the end stages of disease when there is intense 
immunodeficiency. Almost all of these tumors are EBV positive and brain is the most 
common site of tumor [92]. 
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1.1.7 EBV associated epithelial malignancies 
1.1.7.1 Nasopharyngeal carcinoma 
Nasopharyngeal carcinoma (NPC) originates from the squamous epithelial 
cells and classified depending on the degree of differentiation of tumor cells. 
Undifferentiated form of NPC shows most consistent association with EBV and it 
comprises around 100% of total cases of NPCs. This form is characterized by the 
undifferentiated carcinoma cells with heavy lymphocyte infiltration, while EBV present 
latently only in carcinoma cells.      
Like BL, NPC also shows geographical restricted pattern with very high 
incidence in southern China accounting 20% of all adult cancers. In geographical 
regions of Canton and Hong Kong NPC accounts for 25-30 cases per 100 000 
individuals, while it is very rare in Europe and North America with the incidence rate 
of less than 1 per 100 000 individuals [93]. NPC also shows very high incidence in 
Inuit in North America and Greenland and also in Malaysians, Dyaks, Indonesians, 
Filipinos and Vietnamese. In other parts of the world it has very low incidence.  
NPC was linked to EBV based on serological grounds in 1966 [94] and 
confirmation was made with the demonstration of EBV DNA in all malignant epithelial 
cells [95]. Irrespective  of geographical location, 100% of undifferentiated form of NPC 
is EBV associated [96]. EBV in NPC shows latency II gene expression pattern with 
EBNA1, LMP1, LMP2A and LMP2B protein expression along with EBER and 
BamH1A transcripts [97]. LMP1 is assumed to contribute largely in NPC malignancy 
by inhibiting differentiation of tumor cells in culture [42] and by inducing tumorigenic 
phenotype in animals [98]. 
 
1.1.7.2 Gastric carcinoma 
Gastric carcinoma is the second most common carcinoma in the world with 
EBV association that varies between 4-18%. EBV association also related to the 
histology and 80% of the lymphoepithelioma types are EBV positive while none of the 
intestinal and diffuse types are [99]. EBV viral DNA is found as episomal and is clonal. 
EBV expresses EBNA1 only or EBNA1 protein along with LMP2A mRNA, EBER 
and BamH1A transcripts are also expressed [100].  
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1.2 APOPTOSIS AND CANCER 
Apoptosis or programmed cell death is a mechanism responsible for cell 
death that involves genetic regulation. Apoptosis contributes to various processes, such 
as normal cell turnover, development and functioning of immune system and 
embryonic development. Defects in apoptosis can result in various disorders like 
neurodegenerative diseases, autoimmune disorders, ischemic damage and cancer. It is 
characterized by distinct morphological changes like cell shrinkage, membrane 
blebbing, chromatin condensation and nuclear fragmentation [101, 102]. The central 
processes involved in apoptosis are conserved, and most of our knowledge about them 
has emerged from studies done in nematode Caenorhabditis elegans [103].  
Evasion of apoptosis is one of the important mechanisms that cancer cells 
exhibit during the process of carcinogenesis. Cancer cells can express antiapoptotic 
proteins like Bcl-2 or down-regulate pro-apoptotic proteins, such as Bax, tipping the 
balance towards cell survival/ proliferation. Certain B-cell lymphomas such as chronic 
lymphocytic leukemia, overexpress Bcl-2 which gives strong evidence of implication 
of apoptosis in cancer [104]. Tumor cells also show evasion of immune surveillance to 
suppress apoptosis. They show reduced response to death receptor pathway mediated 
apoptosis by FasL. Evasion of apoptosis is also brought about by the expression of non-
functional Fas receptor or secretion of high levels of soluble form of Fas receptor [105, 
106]. Some tumor cells counteract tumor infiltrating lymphocytes (TIL) by Fas ligand 
mediated apoptotic depletion of TILs [107]. Another way of deregulating apoptosis is 
alteration in cell signaling pathways involved in cell cycle progression and/or growth 
arrest. TP53 is a tumor suppressor gene which is mutated in approximately 50 percent 
of all human cancers. Cells expressing wt p53, in response to DNA damage, can cause 
the growth arrest at G1/S phase of cell cycle. If the damage is irreparable, cells undergo 
apoptosis. p53 protein regulates the expression of many genes involved in apoptosis 
like Bcl-2 and Bax [108].  
Mechanism of apoptosis is sophisticated and is energy dependent. There 
are two main pathways involved in apoptosis: intrinsic or mitochondrial pathway and 
extrinsic or death receptor pathway. These two pathways are interconnected and they 
can affect each other [109]. Both these pathways involve aspartyl-specific proteases 
(caspases) with proteolytic activity that cleaves proteins at specific aspartic acid 
residues.  
   19 
Intrinsic pathway results from a variety of non-receptor mediated stimuli, 
resulting in intracellular signaling leading to changes in inner mitochondrial membrane. 
It results in release of two groups of pro-apoptotic proteins from the mitochondrial 
intermembrane space into cytosol [110]. First group made up of cytochrome c, 
Smac/DIABLO, and the serine protease HtrA2/Omi. Second group comprises of AIF, 
endonuclease G and CAD. Members of the Bcl-2 family of proteins control and 
regulate the mitochondrial apoptotic events. They can be both anti-apoptotic or pro-
apoptotic and they work via changing the mitochondrial membrane permeability, thus 
controlling the release of cytochrome C. There are a total of 25 genes included in Bcl-2 
family and the tumor suppressor protein p53 plays an important role in transcriptional 
regulation of these proteins.  
Extrinsic pathway initiates the apoptotic process by transmembrane 
receptor mediated interactions involving death receptors of tumor necrosis factor (TNF) 
receptor subfamily [111]. TNF receptor superfamily contains cysteine rich 
extracellular domain and cytoplasmic death domain [112]. Death domain plays key 
role in transmitting signals from cell surface to intracellular signaling pathways 
leading to apoptosis. Caspase 8 is activated then by the death domains in the intra-
cytoplasmic portion of these receptors and initiates the caspase cascade. 
There is another mechanism of apoptosis brought about by cytotoxic T 
cells mediated via perforin-granzyme dependent cell death, involving granzyme A and 
granzyme B.  Granzyme B is caspase dependent, while granzyme A executes apoptosis 
via caspase independent single stranded DNA damage pathway [113].   
 
1.2.1 Viruses and apoptosis 
In addition to its role in tissue homeostasis and surveillance against tumor 
cells, apoptosis is also an essential component of the cell response to injury, such as 
viral infection. To inhibit virus production and release of progeny virus, infected cell 
tend to undergo programmed cell death. Conversely, viruses have evolved to overcome 
the host cell apoptosis by exploitation of host cellular machinery. Viral responses are 
intended to function in a way that they will prevent premature death of host cell during 
lytic infection and/ or transform host cell while latently infecting them. Viruses, 
however, can also use other mechanisms to overcome hindering effects of apoptosis. 
They can multiply quickly before effective immune response is mounted or in another 
strategy, called cryptic infection virus remains undetected after infection by host [114, 
115].  
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Viruses adopt different mechanisms to inhibit the apoptosis. They can 
disrupt the apoptosis by inhibition of tumor suppressor protein p53, as in case of SV40 
large T binds to p53 and block its functions [7, 116]; papillomavirus E6 and adenovirus 
E1B-55K proteins promote degradation of p53 [117-120]. Some tumor associated 
viruses, like EBV and Kaposi's sarcoma-associated herpesvirus (KSHV), express Bcl-2 
homologues BHRF1 and KSbcl-2, respectively. These Bcl-2 protein homologues show 
anti-apoptotic function and contribute to tumor progression [121, 122]. Adenovirus 
E1B-19K is similar to Bcl-2 protein in sequence and function and is also a distinctive 
example of mimicking Bcl-2 [123, 124]. Many viruses target and modulate the activity 
of TNFR signaling. They express TNFR orthologs [125], can neutralize TNF by 
soluble decoy receptor [126] and can loss [127] or enhance the expression of death 
receptors [128].  Some viruses interfere with the activation of caspases by expressing 
proteins to protect the host cell from apoptosis [129]. Interferon (IFN) plays important 
part in the host response to infection and it does that by inducing cell death via FADD 
protein dependent apoptotic pathway. IFN can also arrest viral life cycle at various 
steps, thus reducing the viral replication and spread. Some tumor viruses also target 
IFNs and their responsive genes to affect IFN mediated antiviral action [130]. 
However, for the host cells successful evasion of apoptosis by viruses is harmful and 
may result into oncogenic transformation of host cell. 
 
1.2.2 EBV and apoptosis 
Many EBV latent proteins are involved in the evasion of apoptosis of host 
cell. LMP1 latent protein is a major factor in EBV mediated evasion of apoptosis. 
LMP1 mimics the constitutively active CD40/ TNF receptor and recruits several TNF 
receptor associated factors at its C terminal activating domains (TRAF), turning on 
TRAFs/NF-B, MAPK and JAK/STAT signal transduction cascades [131]. Activation 
of NF-B pathway results in up-regulation of anti-apoptotic gene products, such as A20 
and cIAPs [132]. NF-B activation also result in inhibition of the BAX promoter 
activity [133] and induction of anti-apoptotic BFL-1 [134]. LMP1 is also shown to 
confer resistance to TGFβ mediated anti-proliferative effect by inducing the expression 
of Id1 [135]. 
EBV encodes two viral BCL-2 homologues, BHRF1 and BALF1, which 
are expressed maximally during the early stages of infection but do not required in 
latently infected cells. However, they prevent the infected cells from apoptosis during 
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early stages of infection [136]. BHRF-1 can directly bind with pro-apoptotic protein 
PUMA and interferes with its function. Moreover, EBV encodes the microRNA, miR-
BART5 [137] and induce cellular microRNA miR-155 [138], which can target PUMA 
transcript. BIK mediated apoptosis can be inhibited by overexpressing BHRF-1 [139].    
Another EBV latent membrane protein, LMP2A, functions like a B-cell 
receptor (BCR) by associating with Syk and the Src family of tyrosine kinases [50]. 
Generally these kinases are recruited to BCR following the antigen binding and results 
into its activation and downstream events that leads to B-cell survival [140]. Moreover, 
LMP2A can induce the expression of anti-apoptotic protein BCL-2 and BCL-XL via 
activation of NF-B [141] and RAS/PI3K/AKT pathway [142], respectively. EBV 
nuclear antigens have also been shown to inhibit apoptosis. EBNA2 can transactivate 
the anti-apoptotic BFL-1 gene [143]. EBNA3 and EBNA6 cooperatively repress the 
expression of the pro-apoptotic protein BIM [144]. In EBV immortalized LCLs, 
EBNA5 froms tri-molecular protein complex with MDM2 and p53, which inhibits 
degradation of p53, but abolishes its transactivational function [41]. 
 
1.2.3 Vitamin D  
The role of Vitamin D is more than a micronutrient and is, actually, 
precursor of a steroid hormone. Biologically most active form of vitamin D is 
1α,25(OH)2D3, also known as calcitriol. Its widely accepted physiological role is to 
maintain calcium homeostasis in body and is vital for normal bone mineralization 
[145]. Dietary vitamin D is present in two forms: vitamin D3 (cholecalciferol) that is 
animal source, while vitamin D2 (ergocalciferol) is a plant source. However, precursor 
of vitamin D3, 7-dehydrocholesterol [7-DHC] or provitamn D3, is present in human 
skin. 7-dehydrocholesterol is converted to cholecalciferol on exposure to UVB 
radiations from Sun. Vitamin D from diet or skin gets into the circulation by binding to 
vitamin D-binding protein (DBP). In liver vitamin D is hydroxylated to form the 
prohormone 25-hydroxy vitamin D [25(OH)D] by the enzyme 25-hydroxylase 
(CYP27A1). 25(OH)D is subsequently converted to calcitirol in kidney by the enzyme 
1α-hydroxylase (CYP27B1).  
Calcitriol exerts its effect by binding to specific nuclear vitamin D 
receptor (VDR) to regulate target gene expression. VDR is a nuclear transcription 
factor that belongs to steroid hormone receptor superfamily, and acts to regulate its 
responsive genes in a ligand dependent manner [146]. VDR is expressed in virtually all 
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tissues, including heart, muscle, breast, kidney, bone, intestine, colon, prostate, brain, 
osteoblasts, and cells of immune system [147].  
Calitriol binds to VDR in cytoplasms and this complex is then transported 
to nucleus by importin In nucleus calcitriol-VDR heterodimerizes with the retinoid 
X receptor (RXR) and its ligand (9 cis-retinoic acid). This heterodimer then binds to 
DNA at vitamin D response element (VDRE) in the promoter region of target genes 
[148]. Calcitriol binding induces phosphorylation and conformational changes to VDR 
which causes the release of co-repressors. Conformational changes also promote the 
binding of stimulatory factors, including chromatin modifiers to VDR by repositioning 
the VDR activation function 2 (AF-2) domains [148].  
 
 
 
Figure 4: Mechanism of Vitamin D genomic action and its effect on cancerogenesis. 1α,25(OH)2D3 binds 
to vitamin D receptor (VDR) in cytoplasm and this complex is translocated to nucleus. Here VDR 
heterodimerizes with retinoid X receptor (RXR) and binds to vitamin D responsive element (VDRE) to 
induce expression of target genes. These genes are involved in apoptosis, differentiation, cell cycle arrest, 
nflammation and immunomodulation. (Adapted from [149]). 
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1.3 WARBURG EFFECT  
One of the distinguishing features of cancer cells from normal cells is 
their altered metabolism. Cancer cells change their metabolic profile to cope up with 
continuous requirement of cell survival and proliferation. The best and oldest known 
metabolic change is increased glycolysis in cancer cells. Otto Warburg in his seminal 
findings observed that cancer cells even in the presence of ample oxygen prefer 
glycolysis over oxidative phosphorylation for the energy production [150]. This 
phenomenon of increased glycolysis at oxygen rich condition is known as aerobic 
glycolysis or Warburg effect. This feature of cancer cells is also exploited clinically for 
the imaging technique; positron emission tomography, using the glucose analogue 
tracer fluorodeoxyglucose (FDG-PET) [151, 152]. In addition to increased glycolysis 
cancer cells also have other metabolic changes, like increased gluconeogenesis, 
glutaminolytic activity, pentose phosphate pathway activity etc.  
 
1.3.1 Glucose metabolism  
Glucose derived from break down of carbohydrates or by 
gluconeogenesis is transported into the cells by specific glucose transporters. Glucose 
gets converted to pyruvate by a fundamental biochemical process called glycolysis and 
this results in production of net two ATP molecules. At oxygen rich conditions, 
pyruvate enters the mitochondria and is converted to acetyl-CoA by the enzyme 
pyruvate dehydrogenase (PDH). Citrate synthase catalyzes condensation reaction 
involving Acetyl CoA and oxaloacetate to produce citrate. Citrate subsequently is 
oxidized in tri-carboxylic acid (TCA) cycle to generate reducing agent NADH, 
electrons and CO2. Electrons from reducing agent passed through electron transport 
chain (ETC) to final electron acceptor oxygen. ETC produces another 34 ATP 
molecules making total 36 molecules of ATP produced from one glucose molecule. 
Only at the anaerobic conditions normal cells produce more lactate from pyruvate when 
oxygen is not available for final electron acceptor in ETC. In contrast, proliferating or 
cancer cells show increased glycolysis and produce more lactate from pyruvate, 
regardless of the availability of oxygen. Lactate produced by cells in glycolysis is 
transported out of the cell by monocarboxylate transporters (MCTs). 
Alternatively, glucose can be metabolized by Pentose phosphate pathway 
(PPP). PPP maintains intracellular nicotinamide adenine dinucleotide phosphate 
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(NADPH), which is critical for cell survival during rapid cell growth and also produces 
ribose sugar for nucleic acid synthesis.  
 
 
Figure 5: Schematic representation of difference in glucose metabolism between normal cell and cancer 
cell. Differentiated cells showed different metabolism at aerobic or anaerobic conditions. They prefer 
mitochondrial respiration at aerobic conditions to produce 36 molecules of ATP per glucose molecule. In 
anaerobic conditions they induce glycolysis and produce 2 molecules of ATP per glucose molecule. 
However, cancer cells prefer glycolysis irrespective of the availability of oxygen. (Adapted from [153]). 
 
1.3.2 Proliferative advantages of glycolysis 
Glycolysis is less efficient way to produce ATPs than oxidative 
phosphorylation (OXPHOS), even though, cancer cells prefer it. Otto Warburg 
proposed that increased aerobic glycolysis is because of impairment in the oxidative 
metabolism [114]. Many studies in tumor cells later showed that they do not have 
defects in oxidative metabolism [115]. So, why proliferating cells show Warburg 
effect? 
Cancer cells are continually exposed to nutrient supply in circulating 
blood and ATP may never be a limiting factor in these cells [153, 154]. Cells, 
exhibiting aerobic glycolysis also show high ratio of ATP/ADP, no matter how often 
they divide [155]. Although ATP production from the glycolysis is low, but if 
glycolytic flux is high, percentage of ATP produced from glycolysis is higher than that 
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of OXPHOS [150, 156]. This is because of high rate of ATP production during 
glycolysis [157], and it is advantageous for the proliferating cells.  
Another explanation is that premalignant tumors expand and outgrow the 
diffusion limits of blood supply, leading to hypoxic tumor microenvironment. Hypoxia 
puts limitation on the oxidative metabolism and tumor cells depend on glycolysis for 
the energy production. Such tumors do produce vascularization by angiogenesis but it 
is disorganized and may not deliver blood effectively and do not completely escape 
cells from hypoxia [158]. Oxygen levels in tumor fluctuate spatiotemporally and it 
results into selection of tumor cell population, which shows constitutively induced 
glycolysis.  
It has also been debated that tumors with increased aerobic glycolysis 
produce lactate and excrete it into the tumor microenvironment resulting, in its 
acidification. This facilitates tumor invasion via destruction of extracellular matrix and 
normal cell population while tumor cells get adapted to this changes [158]. Acidosis 
formed by lactic acid also shown to suppress anticancer immune effectors [159]. 
Glycolysis also functions to support the synthesis of biomolecules like 
nucleotides, amino acids and lipids. Glucose metabolism can provide the precursors to 
build the macromolecules essential for cell division and this is important for the 
generation of daughter cell [160]. NADPH produced during PPP is also required for 
neutralizing reactive oxygen species (ROS) related cellular damage.  
 
1.3.3 Hypoxia inducible factor 1  
  In eukaryotic cells hypoxia inducible factor (HIF) plays an essential role 
in cellular oxygen homeostasis [161-163]. As name suggests, this protein is stabilized 
at the hypoxic conditions which are caused by mismatch between oxygen delivery and 
its consumption. HIF induces transcription of more than 60 proteins, which are 
responsible for oxygen delivery and utilization at low availability of oxygen. This is 
achieved by reduced consumption of oxygen (by inducing glycolysis) or facilitating 
delivery of oxygen (via erythropoiesis or angiogenesis).  
Hypoxia inducible factor 1 (HIF1) is heterodimeric DNA binding 
transcription factor that belongs to the bHLH-PAS (Per/Arnt/Sim) family and consists 
of two subunits- HIF1 and HIF1 [164]. HIF1is oxygen regulated subunit, 
whileHIF1 which isalso called as aryl hydrocarbon receptor nuclear translocator 
(ARNT), is constitutively expressed. At normoxic conditions HIF1is hydroxylated on 
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proline 402 and/ or proline 564 within its oxygen dependent domain (ODD). 
Hydroxylation is catalyzed by the enzymes prolyl hydroxylase domain proteins (PHD), 
which uses O2 and α-ketoglutarate as substrates [165]. The hydroxylated HIF1is 
recognized then by the von Hippel-Lindau tumor suppressor protein (VHL) complexed 
with elongins B and C. VHL is an E3 ubiquitin ligase which targets HIF1 for the 
proteosomal degradation [166, 167]. In hypoxia, when internal partial pressure of 
oxygen is less than 10-15 mm Hg in context of tumors [168, 169], PHD cannot 
hydroxylate HIF1due to lack of oxygen. Thus HIF1cannot be recognized by 
theVHL tumor suppressor, avoids proteosomal degradation and becomes stabilized. 
 
 
Figure 6: Mechanism of HIF1stabilization. (Adapted from [170]) 
 
1.3.4 HIF activators at aerobic condition 
HIF1 plays an important role in cancer progression at the hypoxic conditions.  
However, all cancers are not hypoxic, but HIF1 still plays important role in them. In 
some cases, oncogenic signaling results into HIF1 stabilization in O2 independent 
manner. Expression of HRAS-v12 leads to accumulation of HIF1 at hypoxic as well 
as normoxic conditions [171], while expression of SRC [172] and eRBB2 [173] results 
into increased level of HIF1 at normoxic conditions. Activation of Ras-MAPK 
(mitogen activated protein kinase) [174]  and PI3K pathways [175] can also lead to 
stabilization of HIF1proteinat oxygen rich conditions. Effect of PI3K induced 
HIF1 accumulation could be due to direct activation of PI3K or its downstream kinase 
Akt or loss of inhibitor PTEN tumor suppressor. HIF1 protein translation increases 
due to Akt dependent activation of mammalian target of rapamycin (mTOR) [176].  
   27 
Alteration in mitochondrial metabolism also results in stabilization of 
HIF1. TCA cycle enzymes provide positive feedback mechanism to stabilize HIF1.  
Loss of function of succinate dehydrogenase (SDH) and fumarate hydratase (FH) 
results in the accumulation of substrate for these enzymes, i.e. succinate and fumerate, 
respectively. They can leak into cytosol and compete with -ketogluterate for the 
binding with PHDs (responsible for hydroxylation of HIF1 inhibiting catalytic 
activity of PHDs. It results into the inhibition of hydroxylation and proteosomal 
degradation of HIF1 protein [177-180]. Another TCA cycle enzyme, isocitrate 
dehydrogenase (IDH), in contrast, limits the availability of -ketogluterate required for 
activity of PHDs [181].itochondrial reactive oxygen species (ROS), generated 
during electron transport chain, can also signal to stabilize the level of HIF1 [182-
184]. Hydrogen peroxide (H2O2) in particular oxidizes Fe
2+ 
to Fe
3+
. Fe
2+ 
can act as co-
activator for PHDs
 
for the hydroxylation of HIF1 but Fe3+ can’t. Due to decrease of 
Fe
2+
, PHDs cannot hydroxylate HIF1 and HIF1 escapes proteosomal degradation 
and is stabilized [185].  
 
1.3.5 HIF1 regulation of glycolysis 
HIF1 regulates glycolysis in several ways. The largest group of genes 
regulated by HIF1 is involved in glycolysis [186-188]. Intake of glucose from blood 
into cells requires specific glucose transporters. There are 13 different glucose 
transporters. However, HIF1 induces the expression of GLUT1 and GLUT3, which 
import the major portion of intracellular glucose [189]. After the intake, glucose is 
phosphporylated to glucose-6-phosphate by the enzyme hexokinase (HK). Glucose-6-
phosphate can also enter pentose phosphate pathway, which is another pathway of 
glucose metabolism that is involved in the synthesis of glycogen or structural 
component of glycoproteins. However, HIF1 induces HKI and HKII and also many 
other enzymes involved in Embeden mayerhoff pathway (EMP) (Glycolysis), which 
channels glucose via EMP. Once the glucose is phosphorylated, it can’t escape the cell. 
Phosphorylated glucose molecule is converted to pyruvate via series of enzymatic 
processes. Almost all the enzymes, that are necessary for this process, are regulated by 
HIF1 [161, 190].  
 Pyruvate can be converted to acetyl coenzyme A (AcCoA) by pyruvate 
dehydrogenase (PDH) and after that enters into tricarboxylic acid (TCA) cycle. 
Pyruvate can also be converted to lactate by lactate dehydrogenase A (LDHA) and 
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secreted out of cell. HIF1 induces the expression of pyruvate dehydrogenase kinase 1 
(PDK1), which phosphorylates and inactivates the catalytic domain of the PDH [191]. 
This inhibits entry of pyruvate into the TCA cycle in mitochondria and attenuates 
oxidative phosphorylation [192]. This can result into accumulation of pyruvate which is 
harmful to the cell. HIF1 induces LDHA to convert pyruvate to lactate [193], and also 
monocarboxylate transporter 4 (MCT4), to transfer the lactate into extracellular space 
[194].    
  
Figure 7: Regulation of glycolysis by HIF1 HIF1 activation leads to increase in glycolysis and a 
decrease in oxidative phosphorylation. HIF1 stimulates increased uptake of Glucose by glucose 
transporters (GLUT) that is then metabolized by increased expression of glycolytic enzymes. Pyruvate 
produced as a result of glycolysis will then be converted to lactate by lactate dehydrogenase A (LDHA) 
and excreted from the cell by monocarboxylate transporters 4 (MCT4). Pyruvate dehydrogenase kinase 1 
(PDK1) decreases flow of pyruvate to mitochondria and there is switch of more efficient isoform from 
cytochrome oxidase subunit 4 isoform 1 (COX4I1) to COX4I2 subunit. (Adapted from [170]) 
 
1.3.6 Important HIF1 regulated molecules in glycolysis 
Hexokinase (HK) is responsible for the ATP dependent phosphorylation 
of glucose to glucose-6-phosphate.  HK gene family consists of 4 isoforms, HK I-IV. 
HK II is highly expressed during early carcinogenic events in liver and pancreatic cells; 
HK I is upregulated at lesser extent and HK IV is downregulated [195-198]. HK I and 
II can directly interact with specific voltage-dependent anion channels (VDACs) in 
mitochondria, and this results in inhibition of VDACs function, i.e. shuttling of ATPs 
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between mitochondrial matrix and cytosolic compartment. Secondly, it also influences 
on the interaction of BAX/BAK with VDAC; hence, inhibiting apoptosis. Accumulated 
ATP is harnessed by HK for the phosphorylation of glucose, thus committing glucose 
through glycolysis [199].  
Proliferating cells need energy as well as macromolecules for the cell 
division. Pyruvate kinase (PK) seems to play an important role in this context. In the 
final step of glycolysis it converts phosphoenolpyruvate to pyruvate, producing ATP 
molecules. There are 4 forms of PK (L, R, M1 and M2) which are expressed from two 
genes. PKM1 and PKM2 are isoforms from the same gene; PKM2 is the predominant 
form of the PK in cancer cells. M2 isoform is expressed in embryonic tissue and it is 
rapidly replaced by the M1 isoform during the developmental stages; in cancer cells 
M2 isoform is re-expressed [200]. PKM2 activity is depended on its quaternary 
structure and its tetrameric form is active one [201]. PKM2 is allosterically activated by 
fructose-1,6-bisphosphate (FBP) [202]. PKM2 has less catalytic activity than M1 
isoform and PKM2 promotes both aerobic glycolysis and anabolic metabolism [155]. 
Low activity of PKM2 is advantageous for proliferating cells, because it allows 
glycolytic intermediate to be used for biosynthetic pathway. mTOR induces PKM2 via 
HIF1 [203] and PKM2 is shown to upregulate HIF1activity by direct binding [204], 
thus, creating positive feedback loop between HIF1 and PKM2.  
Table 2: HIF1 transactivating genes that regulate glucose metabolism. 
HIF1 responsive genes Role in metabolism 
GLUT-I , GLUT-III Glucose entry into the cell 
HK Phosphorylation of glucose. 
PGI, PFK1, aldolase, TPI, GAPDH, PGK, 
PGM, enolase, PK, PFKFB1–4 
Glycolysis  
LDHA Conversion of pyruvate to lactate. 
MCT4 Removal of lactate from the cell  
PDK1, MXI1 Decreased mitochondrial activity 
COX4I2, LON protease Increased O2 consumption in hypoxia 
COX4I2, cytochrome oxidase isoform 2; GAPDH, glyceraldehyde-3-phosphate dehydrogenase; GLUT, 
glucose transporter; HIF, hypoxia-inducible factor; HK, hexokinase; LDHA, lactate dehydrogenase A; 
McT, monocarboxylate trasporter; MXI, max interactor; PDK, pyruvate dehydrogenase kinase; PFK, 
phosphofructokinase; PFKFB, 6-phospho-2-kinase/fructose 2,6 bisphosphatase; PGK, phosphoglycerate 
kinase; PGI, phosphoglucose isomerase; PGM, phosphoglycerate mutase; PK, pyruvate kinase; 
TPI, triosephosphate isomerase. 
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1.4 MITOCHONDRIAL RIBOSOME 
Mitochondria are considered to be descendent of eubacteria that 
incorporated into pre-eukaryotic cell during evolution by endosymbiosis [205]. They 
have their own DNA and ribosome for translation. Mitochondrial ribosomes are 
responsible for the translation of all the 13 mRNAs encoded by mitochondrial DNA, 
and translated proteins are essential for the oxidative phosphorylation system. 
Mammalian mitochondrial ribosome (55S) differs from that of cytoplasmic (80S) and 
bacterial ribosome (70S).  It is made up of large (39S) subunits and small (28S) 
subunits. Ancestral mitochondrial ribosome (70S) has been remodeled during the 
evolution to current mitoribosome (55S) and has lost half of its rRNA which are 
replaced by proteins (about 80) [206]. These extra proteins which are not homologous 
to bacterial or cytoplasmic ribosome seem to have extra-ribosomal function. For  
instance,  MRPS29, a GTP binding protein implicated to be involved in apoptosis 
[207]. The small subunit of the mitochondrial ribosome contains 30 proteins. Large 
subunit is made up of 48 proteins making 78 proteins in mitochondrial ribosome [208]. 
All of the mitochondrial ribosomal proteins (MRP) are encoded by nuclear genome, 
translated in cytoplasmic ribosome and imported into the mitochondria. At least 1500 
gene products are translated and migrated to the mitochondria [108, 109]. 
 
1.4.1 Mitochondrial ribosomal protein S18-2  
Mitochondrial ribosomal S18-2 protein belongs to S18 family proteins 
which contain three variants in mammals, MRPS18-1 (AAD34129), MRPS18-2 
(NP_054765) and MRPS18-3 (NP_060605), also termed as MRPS18C, B and A 
respectively. Three variants of S18 homologues are also found in D. melanogaster and 
mouse, while two corresponding to MRPS18-1 and MRPS18-2 are found in C. elegans 
mitochondrial ribosomes [209]. E. coli contains one form while other prokaryotes like 
Streptomyces coelicolor and Mycobacterium tuberculosis contains two variants of this 
protein. Like E. coli, yeast also contains one form which is closer to S18-1. Amino acid 
sequence alignment amongst three forms shows a conserved region in the central part 
of the proteins. Primary sequence of human variants is more related to prokaryotic 
homologue than to each other. S18-1 gene is mapped on the chromosome 4 at 4q21.23 
while genes for other two are located on chromosome 6, MRPS18-2 at 6p21.3 and 
MRPS18-3 at 6p21.1. 
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2 AIMS 
 
The goal of the thesis is to elucidate the role of some EBNA binding cellular 
proteins in cell transformation.  
 
The specific aims were: 
 
 How does EBV counteract Vitamine D induced apoptosis in B cells? 
 
 Study on the role of HIF1in the EBV induced B-cell transformation. 
 
 To explore the role of MRPS18-2 in cell transformation, using rat 
embryonic and terminally differentiated skin fibroblasts. 
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3 RESULTS AND DISCUSSION 
 
3.1.1 Vitamin D in apoptosis 
Calcitriol (1α,25(OH)2D3) exert anti-tumor effect by regulating few key 
mediators of the apoptotic pathway. They can repress the expression of anti-apoptotic 
proteins or upregulate pro-apoptotic proteins. In MCF7 breast carcinoma cells and HL-
60 leukemia cells calcitriol downregulates Bcl-2 expression. In prostate cancer, 
colorectal adenoma and carcinoma cells calcitriol induces the expression of BAX and 
BAK [210]. Calcitriol destabilizes telomerase reverse transcriptase (TERT) mRNA, 
thus promoting apoptosis due to downregulation of telomerase activity and telomere 
erosion [211]. In LNCaP human prostate cancer cells, calcitriol induces apoptosis with 
simultaneous downregulation of antiapoptotic proteins Bcl-2 and Bcl-Xs. 
Overexpression of Bcl-2 in these cells blocks calcitriol induced apoptosis and reduces 
calcitriol induced growth inhibition [212].  
Pre-treatment of calcitriol can sensitize BCa (breast cancer cell line) cells 
for apoptosis. They are more susceptible to apoptosis triggered by reactive oxygen 
species (ROS). Caspase dependent and independent pathways are induced causing 
mitochondrial membrane damage with subsequent release of cytochrome C [213]. 
Calcitriol can also increase cytotoxicity of TNFon the same cells[214]. Calcitriol 
increases the intracellular level of calcium by activating calcium entry from 
extracellular spaces and by depleting calcium stores in endoplasmic reticulum. It is 
detrimental to MCF7 cells, which do not express calbindin-D, that buffers intracellular 
calcium levels, resulting in activation of mu-calpain and caspase-12 and subsequent 
apoptosis [215]. Calcitriol can activate mitogen activated protein kinase (MAPK) 
pathways; p38 and JNK. Activation of these pathways play a role in calcitriol induced 
apoptosis in BCa cells [216]. Promoter of PTEN tumor suppressor gene contains 
VDRE. Upregulation of PTEN via VDR can attenuate PI3 kinase pathway, resulting in 
apoptosis in gastric cancer cells [217]. 
In a previous work of our group, on expression of nuclear receptors in EBV 
transformed B-cells, it was found that VDR is expressed at lower levels in LCLs 
compared to naive and mitogen activated B cells [218]. It has been also shown that 
VDR is constitutively expressed at mRNA and protein level in B-cells and there is a 
functional block for the l,25-(OH),D3 mediated gene regulation in these cells [219]. 
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EBV has been known to protect infected B-cells from apoptosis via its 
latent encoded proteins [220]. EBNA3 family proteins inhibit apoptosis of Burkitt 
lymphoma cells infected with EBNA2 deleted virus [221]. They can suppress the 
transcription of BIM, resulting in anti-apoptotic effect [144]. EBNA3 was also shown to 
regulate the function of another nuclear receptor, aryl hydrocarbon receptor (AhR) thus 
shown to influence the transcription of AhR responsive genes upon its ligand binding, 
protecting cells from apoptosis [222]. 
 
3.1.2 EBNA3 binds to VDR 
 Using mass spectrometry, we aimed to find EBNA3 binding proteins 
after immunoprecipitations. To achieve higher expression of EBNA3, GFP-EBNA3 
was overexpressed in MCF7 cell lines. GFP-EBNA3 containing protein complexes 
were collected by immunoprecipitations using anti-GFP antibody. Few specific bands 
on SDS PAGE which were absent in negative control were analyzed by mass 
spectrometry. We have found SW1/SNF proteins on EBNA3, and one of the subunit of 
this complex was VDR. VDR could be immunoprecipitated with anti-EBNA3 antibody 
from LCL cell lysate. This interaction was confirmed with reverse 
immunoprecipitaions with anti-VDR antibody and detection of EBNA3 by western 
blotting (Fig. 1, Paper I).  
After we found that endogenous EBNA3 and VDR were captured in one 
immunocomplex, we investigated the expression of VDR responsive genes. It was 
measured in the isogenic lymphoblastoid cell lines, expressing EBNA3 (BK-LCL) and 
cells where EBNA3 gene was replaced by neomycine gene (EBNA3-BK-LCL). The 
VDR responsive genes (C-FOS, CYCLIN C, CYP24A1, GADD45A, and P21) were 
expressed at low level in BK-LCL compared to EBNA3-BK-LCL (Fig. 4A, Paper I). 
Same isogenic cell lines were treated with VDR ligand 1-alpha-25-dihydroxyvitamin-
D3 (1,25(OH)2D3) and expression of VDR responsive genes were measured. 
1,25(OH)2D3, treated BK-LCL did show higher expression of VDR responsive genes 
than untreated cells, however, this induction is lower than 1,25(OH)2D3 treated 
EBNA3-BK-LCL cells (Fig. 4B, Paper  I). In another set of experiment, EBV 
negative BL DG75 sub-lines that express either EBNA5 (DG75-EBNA5) or EBNA3 
(DG75-EBNA3) were studied. After treatment with 1,25(OH)2D3, genes such as 
CYCLIN C, CYP24A1, GADD45A and P21, showed up-regulation in DG75-EBNA5 
cells compared to untreated cells, while 1,25(OH)2D3 treatment did not induce 
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responsive genes induction in DG75-EBNA3 cells (Fig. 4C, Paper  I) . These results 
demonstrate that EBNA3 plays a crucial role in repressing VDR responsive genes 
expression in LCLs. 
 
3.1.3 EBNA3 counteracts vitamin D3-induced cell death  
As many VDR responsive gens are pro-apoptotic and they were repressed 
by EBNA3, we wanted to see the physiological relevance of binding between EBNA3 
and VDR. To do that, the proliferation rate of freshly established LCLs, BK-LCL and 
EBNA3-BK-LCL were assessed. Cells were cultured in medium that contained 1.10-7 
M of 1,25(OH)2D3 and in the ordinary medium. Untreated EBNA3-BK-LCL 
proliferated slower than untreated LCL and BK-LCL, which proves that EBNA3 is 
necessary for efficient transformation. Treatment of EBNA3-BK-LCL with 
1,25(OH)2D3 decreased the proliferation rate significantly compared with untreated 
cells while LCL and BK-LCL  did not show any difference upon treatment. This shows 
that in absence of EBNA3 cells are vulnerable to 1,25(OH)2D3 mediated cell death and 
EBNA3 protects LCLs from 1,25(OH)2D3 induced cell death (Fig. 5A, Paper  I) . 
Annexin V assay showed that more than 90 % of the EBNA3-BK-LCL 
cells were apoptotic upon treatment with 1,25(OH)2D3.  1,25(OH)2D3 was used to treat 
cells at the higher levels compared with physiological levels but still EBNA3 could 
save LCL from 1,25(OH)2D3 induced cell death (Fig. 5B, Paper  I).   
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3.2 VIRUSES AND GLYCOLYSIS 
Few studies done in 1970s and before showed that the virally transformed 
cells, such as transformed chick embryo cells by RSV [223], feline fibroblasts 
transformed by Feline leukemia virus and HEp-2 cells [224] and monkey kidney cells 
transformed by poliomyelitis virus [225] has increased glycolysis. More recently, there 
was work done on metabolic changes upon infection by tumor viruses. In a global 
approach to study the effect of cytomegalovirus (CMV) infection on host cell 
metabolism, 63 different intracellular metabolites were measured at different time 
points after infection, using liquid chromatography-tandem mass spectrometry. It was 
observed that with the progression of infection, metabolites that are involved in 
glycolysis, the citric acid cycle, and pyrimidine nucleotide biosynthesis increased. This 
increase was also confirmed by transcriptional up-regulation of enzymes involved in 
glycolysis and citric acid cycle [226]. In another metabolomics approach to check the 
host cell metabolic changes after infection of endothelial cells with Kaposi sarcoma 
herpes virus (KSHV), one third of the 194 different biochemicals were found to be 
altered. The number of metabolic pathways altered in KSHV infected cells was similar 
to cancer cells. This concerns amino acid metabolism and many glycolytic 
intermediates like 3-phosphoglycerate, 2-phosphoglycerate and phosphoenolpyruvate 
(PEP). The pentose phosphate pathway intermediates like ribose 5-phosphate, ribulose 
5-phosphate and/or xylulose 5-phosphate were elevated significantly in KSHV infected 
samples. Metabolites involved in de novo fatty acid synthesis were significantly 
increased in KSHV infected cells. Inhibition of fatty acid synthesis resulted in induction 
of apoptosis in infected cells [227]. E7 oncoprotein encoded by Human papilloma virus 
(HPV) interacts with the glycolytic enzyme PKM2 which catalyzes the final step of the 
glycolysis, converting phosphoenolpyruvate to pyruvate. PKM2 is activated when it 
forms a tetramer, while interaction with E7 stabilizes it in dimeric inactivated form. So, 
this could be in favor of the glucose molecule to be used via pentose phosphate 
pathway that gives biosynthetic advantages to the cell [228].  
 
3.2.1 HIF1 is stabilized in lymphoblastoid cells (LCLs) 
In our study we have found that HIF1 transcription factor is stabilized in 
EBV immortalized lymphoblastoid cells at the normal cell culture conditions. 
Concurrent with this, there is no change in the mRNA expression level between LCLs 
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and activated B-cells (Fig. 1, Paper II). This indicates that HIF1is regulated at 
proteinlevel rather than at the RNA level. We further checked if any of EBNAs play a 
role in stabilization of HIF1y GST pull down assays, EBNA3 but not EBNA 5 and 
6 are found to be associated with the HIF1. This interaction was also confirmed by the 
immunoprecipitation with EBNA3 antibody immobilized on CNBr beads (Fig. 2A and 
B, Paper II).  
We further investigated the cellular distribution of the HIF1, EBNAs and 
HIF1hydroxylating enzymes, prolyl hydroxylases (PHDs 1 and 2). HIF1 was found 
to be nuclear, while it was almost absent in the nucleus in mitogen activated B-cells. 
This was also confirmed by immunoblotting, using subcellular fractions, that showed 
higher HIF1 levels in nuclear fraction of LCL (Fig. 4, Paper II). HIF1 was found to 
be co-localized with EBNA3 and partially with EBNA5 in MCF7 breast carcinoma cell 
line when EBNAs were overexpressed after transient transfection. In the same system, 
PHDs 1 and 2 which are mainly cytoplasmic could be localized to the nucleus. PHD1 
co-localized with HIF1 and EBNA5, while PHD2 was found to be co-localized with 
HIF1 and EBNA3 (Fig. 2 C and D, Paper II). We next performed GST pull down 
assays and verified that PHD1 form complex with EBNA5, while PHD2 with EBNA3 
(Fig. 3, Paper II). These results indicate that stabilization of HIF1 in LCLs could be 
due to impairment of function of HIF1 hydroxylating enzymes, PHDs. This 
interaction may impair the catalytic activity of PHDs due to steric hindrance.    
 
3.2.2 HIF1induces aerobic glycolysis (Warburg effect) inLCLs 
In spite being in complex with EBNA3, HIF1 was found to be 
transcriptionally active. Quantitative PCR was performed to check the expression of 
HIF1 responsive genes in LCLs, freshly EBV infected cells and the mitogen activated 
B-cells. Many HIF1 responsive genes were up-regulated in LCLs and freshly EBV 
infected B-cells compared to mitogen activated B-cells. Mitogen activated B cells, 
treated with hypoxia mimicking compound, which stabilizes HIF1, showed up-
regulation of responsive genes. This is in contrast to LCLs and freshly EBV infected 
cell in which HIF1responsive genes were expressed at higher level under all 
conditions. 
 LCLs do not experience hypoxia in culture conditions but they do 
stabilize the protein responsible for dealing with hypoxic situation. So, we looked for 
other functions of HIF1 It has also been shown to modulate cellular metabolism by 
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inducing genes involved in glycolysis and attenuating the mitochondrial oxidative 
metabolism. We examined whether HIF1 plays any role in glycolysis in LCLs or not. 
We found that at mRNA level, HIF1 activate many genes which induce glycolysis in 
LCLs that exhibit Warburg effect (Fig. 5, Paper II).  GLUT1 (glucose transporter), 
which imports glucose to cell, and enzymes like PFKL (phosphofructokinase), HK1 
(hexokinase) and PKLR (pyruvate kinase), PGK1 (phosphoglycerate kinase), which are 
involved in glycolysis process, were up-regulated in LCLs. LDHA (lactate 
dehydrogenase), which converts pyruvate to lactate, and MCT4, (monocarboxylate 
transporter) which exports lactate out of the cell, were also induced. PDK1 (pyruvate 
dehydrogenase kinase), which stops pyruvate entry into mitochondria by inhibiting the 
catalytic activity of the enzyme pyruvate dehydrogenase (PDH) [191] was also up-
regulated. However, production of reactive oxygen species (ROS) in LCLs was 
observed to be very high (Fig. 6B, Paper II), indicating that even though PDK1 inhibit 
entry of pyruvate (that fuels mitochondrial respiration), mitochondrial respiration is not 
completely abolished in LCLs.  
Moreover, the end product of glycolysis, i.e. pyruvate, was produced 5 
times more in LCLs, than in activated B-cells and freshly EBV infected cells. 
Enzymatic activity of lactate dehydrogenase A (LDHA), which converts pyruvate to 
lactate, was also extremely up-regulated in LCLs that was also revealed by the lactate 
measurement from the medium of the cells. LCLs showed 10 fold more lactate 
production compared to the mitogen activated and freshly EBV infected B-cells (Fig. 
6A, Paper II).  Thus, up-regulation of glycolysis with increased lactate production in 
LCL shows that they exhibit Warburg effect and HIF1plays an important role in this 
phenomenon.    
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3.3 MRPS18B (S18-2) CAN INDUCE CELL TRANSFORMATION 
3.3.1 Overexpression of S18–2 immortalizes REFs 
S18- 2 was first cloned from CD34+ hematopoietic stem/progenitor cells 
[229]. It serves as a bridge between EBNA6 and RB in EBV transformed B-cells. 
EBNA6 binds to S18-2 and targets it to the nucleus, thus promoting its binding to RB. 
S18-2 binds to RB at the same pocket where RB has binding site for E2F1. Thus, S18-2 
competes with E2F1 for binding with RB and EBNA6 expressing cells shows increased 
level of free E2F1 compared to EBNA6 null cells [230]. This promotes the cell cycle 
progression from G1 to S phase.  
 
Figure 8: Mechanism of S18-2 mediated cell cycle progression in EBV infected B-cells. In resting B 
cells pRb is in bound state with E2F1, while S18-2 is present in cytoplasm. After EBV infection EBNA-6 
binds and translocates S18-2 to nucleus. In nucleus S18-2 competes with E2F1 for the binding to pRb. 
This results in increased amount of free E2F1 and cell enters into S-phase of the cell cycle. (adapted from 
[230]) 
 
 
It was shown earlier that EBNA6 is an immortalizing onco-protein and 
can co-operate with Ha-Ras in transformation of REFs [35]. As EBNA6 uses S18-2 to 
induce S-phase entry we thought that it might be possible that S18-2 has its own role in 
cell transformation. To study this hypothesis, we decided to check whether S18-2 can 
co-operate with Ha-Ras or EBNA6 in classical rat embryonic fibroblasts (REFs) 
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transformation assay. GFP fused S18-2, carrying neomycin resistance gene, was 
overexpressed alone or in combination with Ha-Ras or EBNA6 in REFs. Transfected 
cells were cultured on G418 selection medium for 2 weeks. Surprisingly, S18-2 alone 
was able to induce massive transformation of REFs. Large colonies were formed in 
petri dishes, where un-transfected control cells died in a week on selection medium. 
This result was also obtained by transfecting cells with c-myc-tagged S18–2 (MTS18–
2) and pBabe-S18–2 (in triplicate). Clones from GFP-S18-2 and pBabe-S18–2 
transformed cells were maintained and observed for more than 20 months in culture. To 
verify that for transformation S18-2 protein is needed, mutants lacking ATG start 
codon and mixture of 4 different small interfering RNA oligos designed to antagonize 
S18-2 mRNA were transfected along with non-specific SiRNA as a control. Cell death 
occurred after 48 hours of transfection concurrent with the decrease in S18-2 protein 
level while control siRNA had no such effect.  
 
3.3.2 S18–2-immortalized cells show embryonic stem cell-like 
properties 
S18-2 immortalized cells termed as 18IM, grew as large multilayered foci 
in culture and resembled stem cells growth. 18IM cells, when grown in bacterial petri 
dish, formed large compact aggregates, reminiscent embryoid bodies (Fig.1E, Paper 
III). These embryoid bodies grew normally like 18IM cells when cultured back at the 
ordinary conditions. However, c-myc and mutated Ha-ras transformed REFs (MR) 
formed clumps in bacterial petri dish and did not form embroyid bodies (Fig.1F, Paper 
III). RT- PCR data showed loss of mesenchymal differentiation genes like vimentin and 
FUT4 in 18IM cells but not in REFs. Embryonic stem cell specific genes like Sox2 and 
Oct 3/4 were upregulated in 18IM cells. Further we tested 18IM cells for the expression 
of stem cell markers by immunostainings. 30-40% of 18IM cell showed strong staining 
for stage specific embryonic antigen 1 (SSEA-1), in contrast to REFs and MR. 
Immunostaining data also confirmed that vimentin and smooth muscle actin 
(mesodermal markers) were lost by 18IM cells (Fig.2A and C, Paper III). Strikingly, it 
was found in available microarray data that S18-2 is expressed in embryonic stem cells 
at the higher levels than in differentiated tissues. 
 
3.3.3 18IM cells can differentiate in vitro and in vivo 
Some of the cells from the confluent 18IM cells detached from the 
surface. These cells were collected on cytospin slides. They had large cytoplasmic 
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vacuoles and were positive for the Oil Red O staining specific for the fat cells. No such 
cells were detected in control REF or MR cells. Moreover, rat specific MHC class II 
and ectoderm specific beta-III-tubulin-expressing cells were also found in 18IM 
culture. Cells obtained from re-culturing of embryoid bodies also showed expression of 
ectoderm specific pan-keratin (Fig.2A,B,C and D, Paper III). This indicates that 18IM 
cells could differentiate into cells from other lineages and expressed endoderm and 
ectoderm specific markers.  
 18IM grew in soft agar with high efficiency, a characteristic of 
transformed cells. To study the tumorigenic ability of 18IM cells in vivo, 5 millions of 
cells were inoculated in 5 SCID mice subcutaneously. Small tumors of maximum 
volume of approximately 20 mm
3
 appeared at the site of inoculation in 9-13 days. 
However, after 3-4 weeks they decreased in volume to 2-3 mm
3
 in three mice while 
disappeared in other two. Hematoxylin and eosin staining of the paraffin embedded 
samples revealed morphologically heterogenous anaplastic cells. Single large 
neoplastic cells with prominent nucleoli and cytoplasmic vacuoles were also observed. 
Rat cells could be distinguished by the absence of Hoechst positive pericentromeric 
heterochromatin foci present in mouse cells and fraction of such rat cells show pan-
keratin staining in cytoplasmic filaments. Expression of pan-keratin showed that 18IM 
cells have trans-differentiated in vivo (Fig.4, Paper III).   
 
3.3.4 Expression profile of 18IM and REFs 
The gene expression profile of 18IM cells were compared with REFs by 
microarray technique. Genes, showing more than two fold difference with FDR-
corrected P-value more than 0.05, were chosen for further studies. More than 4000 
genes found to be differentially expressed and 19 cellular pathways altered in 18IM 
cells (Fig.1, Paper IV). Many genes involved in self-renewal pathways like WNT, 
BMP, -catenin (Ctnn-b), Bmpr3 (BMP receptor), Smad1/5/8, Stat3, Spp1, Sox11, and 
Sh3glb1 were up-regulated while genes involved in mesenchymal differentiation like  
Runx2, Hoxc8, Creb, and Tlx2 were downregulated. Also many genes involved in stem 
cell development and proliferation were differently expressed ( Table 1, Paper IV).  
15 genes from microarray data, which were differentially expressed and 
may play a role in stem cell renewal or in carcinogenesis, were validated by 
quantitative PCR. As 18IM cells show stem cell like characteristics, genes involved in 
experimental induction of pluripotency in fibroblasts were also checked by Q-PCR. 
Oct4, Nanog, and Sox2 were found to be up-regulated while C-myc and Klf4 did not 
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show induction in 18IM cells (Fig.2, Paper IV). Notably, C-myc was found to be 
expressed at higher level at protein level in 18IM cells. Western blotting data showed 
loss of vimentin and smooth muscle actin from 18IM cells, while Sox2 was 
overexpressed at the protein level (Fig.3, Paper IV). This confirms the previous RT-
PCR study observations. Moreover, 18IM cells continued to express the embryonic 
stem cell marker SSEA-1 even after 2 years in culture.  
De-methylation of the CpG islands in the promoter region has been 
shown to be the mechanism behind expression of the genes involved in induction of 
pluripotency [231]. So, we investigated the promoter methylation of the 6 genes 
playing the role in this process. Oct4, Nanog, Sox2, Lin-28, C-Myc and Klf4. They 
were analysed by the treatment of cells with sodium bisulfite and subsequent 
sequencing of the amplified fragments from genomic DNA was performed. 8 of the 
clones for each gene from 18IM and REFs were analysed but none of the genes showed 
substantial difference in promoter methylation pattern. 
 
3.3.5 Experiments on newly generated clones 
Three new cell lines were generated, two by overexpression of GFP-S18-
2 and one by another construct pBabe-S18-2, which gives lower expression of the 
protein compared to GFP construct. Three clones namely, clone-10 and 12 from GFP-
S18 -2 and clone-6 from pBabe vector were followed in culture for a year. Clones10 
and 12, like 18IM cells, formed foci with dense center while clone-6 with lower 
expression of S18-2 did not form compact foci and show high degree of cellular 
heterogeneity in culture. None of the clones showed tumor formation in SCID mice two 
months after inoculation. Cloning in soft agar gave colonies from clone-10 and 12 but 
not from clone-6.  
All the clones showed expression of c-myc at protein level. They did not 
lose smooth muscle actin expression, unlike 18IM cells. However, clone-10 and 12 did 
show Oct4 and Sox2 upregulation at the protein level. Clone-6, which gives lower 
expression of the S18-2 protein did not show Oct4 expression or induction of Sox2 as 
high as other clones. Clone-6 also showed expression of mesodermal marker vimentin, 
unlike 18IM and clone10 and 12 (Fig.5, Paper IV). This indicates that level of 
expression of S18-2 might be responsible for determining the degree of differentiation 
of the cells.  
Moreover, inhibition of protein synthesis in zebra fish by introduction of 
the S18-2 specific morpholino resulted in embryonic lethality while simultaneous 
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introduction of in vitro transcribed S18-2 mRNA permitted the normal development of 
the zebra fish.  
 
3.3.6 Immortalization of primary rat skin fibroblasts (RSFs) by 
overexpression of MRPS18-2 
18IM cells formed embryoid bodies and expressed some stem cell 
markers with loss of mesodermal markers. However, they were derived from rat 
embryonic fibroblasts and hence, it might be possible that primary culture contained 
some of the stem cell from rat embryo, i.e. there was a mix population where some 
cells might have stem cell like characters. Therefore, we decided to investigate whether 
S18-2 will immortalize fibroblasts derived from adult tissue of rat or not. To do this, we 
transfected rat skin fibroblasts with GFP-S18-2 and selected cells with G418. After 3 
weeks clones were selected and the fastest growing clones, i.e 3, 6, 13 and 17, were 
expanded in culture flask from petri dish. These cells showed loss of contact inhibiton 
and anchorage independent growth, they were maintained in culture over the period of 
20 months and passed 200 passages. So, the S18-2 protein could indeed immortalize 
the rat skin fibroblasts. However, they did not form embryoid bodies in bacterial petri 
dish. Further we studied a gene expression pattern and expression of differentiation 
markers.  
 Quantitative PCR studies showed that genes involved in induced 
pluripotency, i.e. Sox2, Oct4, Klf4, and c-Myc, were upregulated compared to primary 
RSFs. Transcription factor Tcea3 and elongation factor Eef1a2 which were extremely 
up-regulated in 18IM cells were expressed at lower level in immortalized RSFs (Fig.2, 
Manuscript). Western blotting showed that immortalized clones of RSFs did not lose 
expression of vimentin and smooth muscle actin while they upregulate Oct4, Sox2 and 
c-Myc. Surprisingly, E-cadherine, specific for epithelial cells, showed induction in all 
clones from RSFs and in 18IM cells as well (Fig.3 and 4, Manuscript). Cell cycle 
distribution showed more cells in S-phase or G2-M phase of immortalized REFs and 
RSFs compared to parental primary cells. Immortalized clones (and 18IM) cells also 
showed much higher activity of telomerase enzyme compared to parental cells ((Fig.6 
and 7, Manuscript)). 
 
3.3.7 Study of the tumorigenicity of immortalized cells in SCID mice 
Newly generated clones from rat embryonic fibroblasts and rat skin 
fibroblast were tested for tumorigenicity. Around 2 million cells of each cell line were 
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injected subcutaneously in SCID mice and observed for the tumor growth. To our 
surprise, Clone 10 from immortalized REFs and clone 6 from immortalized RSFs gave 
rise to tumor. Tumors could be palpable after 2 months after inoculation from clone-10 
of REFs and 3 months after inoculation from clone 6 of RSFs (Table 1, Manuscript). 
Mice became cachexic after 5 months and they were sacrificed. Tumors were 
characterized as aggressive invasive fibrosarcomas (Fig.5, Manuscript). They showed 
feature of mesothelial tumor with expression of both mesenchymal (smooth muscle 
actin, partially vimentin) and epithelial (E-cadherin) cell markers.  Notably, previous 
attempts to induce tumors in SCID mice by 18IM or clones from immortalized REFs 
failed. We transplanted cells in 5 mice and we did not observe tumor growth. It might 
be because mice were not observed for long enough period till the development of 
tumor.  
It was reported that tumorigenic conversion of rat embryonic fibroblasts 
require activation of at least two cooperating oncogenes [232]. Subsequent studies in 
same model showed that one activated oncogene can induce tumors without 
requirement of second mutation [233, 234]. Activation of ras alone could transform the 
cells but it was weak in immortalizing cells. C-myc alone could immortalize cells 
potently but failed to induce transformed characteristics efficiently. So, conclusion 
from this study was to induce naturally occurring tumors, activation of multiple 
oncogenes are required. Here, in our study, low S18-2 expressing cells i.e. clones 
derived from pBabe transformed cells did not give tumors in SCID mice nor did they 
form foci in culture. However, overexpression of GFP-S18-2 could immortalize REFs 
as well as transform them as revealed by formation of foci in culture, growth in soft 
agar and their ability to give tumors in SCID mice. In result, as S18-2 can alone 
immortalize and transform cells we can suggest that S18-2 is a putative oncogene.  
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4 CONCLUDING REMARKS 
 
 In result of present work, we have identified new EBV strategies in 
evasion of apoptosis and alteration of cell metabolism to promote the cell 
transformation. Vitamin D receptor (VDR) mediated apoptosis is blocked due to 
binding of VDR with EBNA3 that results in subsequent inactivation of transcriptional 
activity of VDR. According to our data, vitamin D3 shall be given with caution to 
patients with lymphoproliferative disease.  
Under the aerobic culture conditions HIF1is stabilized in LCLs and is 
transcriptionally active. EBNA3 and EBNA5 by binding to prolyl hydroxylases 1 
(PHD1) and 2 (PHD2), respectively, block the hydroxylation of HIF1that inhibits its 
degradation on proteasomal machinery. HIF1favorsglycolysis over oxidative 
phosphorylation in LCLs, probably, to support the biosynthetic needs of the rapidly 
proliferating cells. Our finding makes HIF1the new putative target for anti-cancer 
therapy in patients with lymphoproliferative diseases. Efforts should also be given to 
block the pathways in cellular metabolism orchestrated by HIF1Status of 
HIF1should also be studied in Burkitt lymphoma with special attention on the role of 
EBV.   
My doctoral work resulted in identification of new cellular functions of 
mitochondrial ribosomal protein MRPS18-2 (S18-2), the EBNA6 binding protein. S18-
2 can transform rat embryonic fibroblasts (REFs) as well as adult skin fibroblasts (RSF) 
in culture. Strikingly, established cell line from REFs and RSFs can give tumors in 
SCID mice. Thus, S18-2 protein is a putative oncoprotein and its role in oncogenic 
transformation of cells should be further elucidated.  
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